BioCentury This Week

Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

Mar 22, 2022

Ask episode

Chapters

Transcript

Episode notes

The First Check Point Inhibitor Against a New Target

Aftua Lungibodysan

Investing in a Company That Doesn't Show Monotherapy Eficacy

Optivo and Dua for Two Combination With Flag?

I L to as a Cancer Amutitherapy

What Are Companies Doing to Make It Through These Tough Times?

Are You Considering a Synthetic Royalty Deal?

Getting Bigger Deals in the New Year?

The Byo Century Podcast - Stephen Usden